XJPX
7446
Market cap25mUSD
Oct 09, Last price
4,320.00JPY
1D
-1.93%
1Q
-6.49%
Jan 2017
73.15%
Name
Tohoku Chemical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tohoku Chemical Co., Ltd., a Japanese trading enterprise, distributes an extensive array of products, primarily focusing on chemicals, medical supplies, and agricultural provisions. Its core offerings encompass pesticides, food additives, and a variety of industrial chemicals and reagents, along with their corresponding apparatus. In the healthcare sector, the company provides crucial clinical diagnostic reagents and related equipment, such as kits vital for blood and bacterial analysis that aid medical examinations and disease detection. Their medical portfolio further extends to specialized devices like clinical inspection systems and medical imaging equipment, as well as external diagnostic pharmaceuticals and various medical materials. For the food industry, Tohoku Chemical supplies food additives and processing machinery. The company also furnishes a broad spectrum of reagents for quality control, analytical testing, and hygiene applications, including cleaning agents, pesticides, and water treatment solutions. Additionally, they offer essential materials for research and development, encompassing transfer, analytical inspection, and new product innovation. Within agriculture, their provisions include pesticides, soil conditioning agents, and other farming requisites, alongside agricultural infrastructure like steel greenhouses designed for floriculture. They also market general wellness and healthcare items. Beyond these specialized areas, Tohoku Chemical Co., Ltd. is involved in the sales and maintenance of computing devices, scientific instruments, medical and educational apparatus, and measuring equipment. Furthermore, the company cultivates and sells flowers. Established in 1953, the firm maintains its headquarters in Hirosaki, Japan.
Key people
Yasuyuki Azuma
President, Representative Director · since 2019
Masahiro Kon
Chairman of Subsidiary, Director · since 2019
Manabu Shimazu
Managing Executive Officer, Manager of Group, Director of Industry Sales Group, Director · since 2023
Teietsu Ishimura
Senior Executive Officer, Manager of Yamagata Office, Manager of Yonezawa Center · since 2023
Hajime Sasaki
Senior Executive Officer, Manager of Tokyo Office, Assistant Group Manager of Industry Sales Group · since 2023
Hidekatsu Sugiyama
Senior Executive Officer, Assistant Group Manager of Medical Sales Group · since 2023
Yuzuru Isobe
Executive Officer, Manager of Hachinohe Office, Director of 3rd Group Sales in Hachinohe Office · since 2013
Toshiaki Kanaya
Executive Officer, Manager of Akita Office · since 2013
Keiji Matsuda
Executive Officer, Manager of Hachinohe Office, Director of Hachinohe Industry Sales Group · since 2023
Hiroshi Nakagawa
Executive Officer, Manager of Iwate Office · since 2013
Yukitaka Nishizawa
Executive Officer, Team Leader of Industry Sales Group Food Team in Hachinohe office · since 2023
Makoto Ono
Executive Officer, Manager of Medical Sales Group, Director of Medical Sales Group · since 2023
Shunichi Soma
Executive Officer · since 2023
Osamu Yamada
Executive Officer, Director of Life System Information Research Institute, President of Subsidiary · since 2013
Yasuo Azuma
Chairman of the Board · since 2009
Wataru Nishibori
Managing Executive Officer, Manager of Academia & Life Science Sales Group, Manager of Aomori Office, Manager of MutsuOgawara Sales Office, Manager of Contract Analysis & Program R&D Group, Director · since 2023
Gai Sato
Managing Executive Officer, Senior Manager of 3rd Sales Group, Manager of Sendai Office, Director · since 2019
Eiji Ito
Independent Director · since 2017
Independent Director · since 2015
Tadashi Takasugi
Independent Director · since 2022
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||